Transcription of RITUXAN Prescribing Information - Genentech
{{id}} {{{paragraph}}}
Example: dental hygienist
RITUXAN Prescribing Information - Genentech
HIGHLIGHTS OF Prescribing Information The dose for RA in combination with methotrexate is two-1000 mg These highlights do not include all the Information needed to use intravenous infusions separated by 2 weeks (one course) every 24 weeks RITUXAN safely and effectively. See full Prescribing Information for or based on clinical evaluation, but not sooner than every 16 weeks. RITUXAN . Methylprednisolone 100 mg intravenous or equivalent glucocorticoid is recommended 30 minutes prior to each infusion ( ). RITUXAN (rituximab) injection, for intravenous use . The dose for GPA and MPA in combination with glucocorticoids is Initial Approval: 1997 375 mg/m once weekly for 4 weeks ( ). 2. The dose for PV is two-1000 mg intravenous infusions separated by 2. WARNING: FATAL INFUSION REACTIONS, SEVERE weeks in combination with a tapering course of glucocorticoids, then a MUCOCUTANEOUS REACTIONS, HEPATITIS B VIRUS 500 mg intravenous infusion at Month 12 and every 6 months thereafter or REACTIVATION and PROGRESSIVE MULTIFOCAL based on clinical evaluation.
cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens. 1.2 Chronic Lymphocytic Leukemia (CLL) RITUXAN, in combination with fludarabine and cyclophosphamide (FC), is indicated for the treatment of adult patients with previously untreated and previously treated CD20-positive CLL.
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: